PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Announcing the third cohort of the Hevolution/AFAR new investigator awards in aging biology and geroscience research

$6,750,000 will support 18 junior investigators studying age-related diseases and healthspan

2025-12-09
(Press-News.org)

New York, NY —The American Federation for Aging Research (AFAR) and Hevolution Foundation are pleased to announce the third cohort of the Hevolution/AFAR New Investigator Awardees in Aging Biology and Geroscience Research. This grant program enables junior investigators with labs in the US and Canada, and with at least three years of independent research, to advance research projects in basic biology of aging, as well as geroscience projects that translate advances in basic research on aging biology from the laboratory to the clinic, paving the way for healthspan-expanding therapeutics and treatments. $6,750,000 will support eighteen investigators selected to receive this three-year award of $375,000 (total):

Huan Bao, PhD, Associate Professor, University of Virginia: Molecular mechanisms of Annexin-mediated membrane repair in preventing premature senescence Itay Budin, PhD, Associate Professor of Biochemistry & Molecular Biophysics, University of California San Diego: 
Functional roles of plasmalogens and their loss in aging cell membranes Junyue Cao, PhD, Associate Professor, The Rockefeller University: Decipher the Cell Regulatory Network of Mammalian Aging at the Scale of the Whole Organism Brianne Connizzo, PhD, Assistant Professor in Biomedical and Mechanical Engineering, Boston University: Senescence Disrupts Tissue Remodeling and Repair Jia Guo, PhD, Assistant Professor, Columbia University: Mapping the Spatial-Temporal Patterns of Normal Brain Aging Using Multi-Site T1w Structural MRI and AI-Driven CBV Analysis Ramin Herati, MD, Assistant Professor, NYU Grossman School of Medicine: Echoes of the past: mechanisms of poor vaccine responses due to age-associated inflammation Weishan Huang, PhD, Associate Professor, Louisiana State University: Mechanisms of Lung Immune Memory Decline During Aging Emma Johnson, PhD, Assistant Professor, Washington University School of Medicine: Elucidating environmental context-dependent genetic variation related to aging and lifespan in humans Hongjie Li, PhD, Assistant Professor, Baylor College of Medicine: Building Systematic Brain-Body Communication and Personalized Aging Trajectories Katharina Maisel, PhD, Associate Professor, University of Maryland: Investigating changes in the physical environment in the lymph node that alter immune cell functions in aging Jerome Mertens, PhD, Associate Professor, University of California San Diego: Metabolic regulation of resilience in aging human neurons Hadi Nia, PhD, Assistant Professor of Biomedical Engineering, Boston University: Inflammaging in the Lung: Dissecting the Impact of Aging on pulmonary vs. circulatory factors Mattia Quattrocelli, PhD, Assistant Professor, University of Cincinnati: The Carnosine Clock Ticks for Healthy Aging Jason Sheltzer, PhD, Assistant Professor, Stanford University: Investigating loss of the Y chromosome as a targetable driver of aging-related pathologies Noah Snyder-Mackler, PhD, Associate Professor, Arizona State University: Molecular causes and consequences of inter- and intra-individual heterogeneity in aging Peter van Galen, PhD, Assistant Professor of Medicine, Harvard Medical School, Brigham and Women's Hospital: Hematopoietic Stem Cell Diversity Driving Age-Associated Inflammation Deborah Winter, PhD, Associate Professor, Northwestern University: Understanding the role of noisy chromatin deregulation in aging macrophages Tuoqi Wu, PhD, Tenure-Track Assistant Professor, University of Texas Southwestern Medical Center: Understand FOXP1 as a gatekeeper of T cell aging

AFAR and Hevolution Foundation launched the New Investigator Awards in 2022 as a pilot initiative to support research projects in the basicbiology of aging and geroscience—a research paradigm based on addressing the biology of aging and age-related diseases to promotehealthy aging. To date, Hevolution Foundation committed more than $24 million to support 54 New Investigators.

“The Hevolution/AFAR New Investigator Awards in Aging Biology and Geroscience continue to be a powerful catalyst for the next generation of aging researchers. In just a few years, Hevolution has been able to bring increased global attention, credibility, and meaningful funding to this field by working with highly respected and rusted partners like AFAR, said Dr. Mehmodd Khan, CEO of Hevolution Foundation.  Supporting emerging talent is central to our mission because their work shapes the future of healthspan science. Our investment reflects our belief in these early-career scientists and the real impact their research will have in advancing healthy aging for people everywhere.”

The New Investigator Award recipients are selected through AFAR's vigorous review process led by a committee of accomplished scientists representing a wide range of expertise in biomedical research on aging; Holly Van Remmen, PhD (Aging & Metabolism Research Program Chair at the Oklahoma Medical Research Foundation and holds the G.T. Blankenship Chair in Aging Research) served as the Chair of the selection committee.

"For more than four decades, AFAR has supported the most promising and talented emerging investigators in the basic biology of aging. Our efforts have been a catalyst for advancing the understanding of basic aging processes. This understanding in turn has shaped the foundation of geroscience that these New Investigator Awardees can now build upon," notes Steven N. Austad, PhD, AFAR ScientificDirector. "AFAR eagerly anticipates the impact that this third cohort of New Investigators will make and is grateful for Hevolution Foundation’s support."

Hevolution Foundation also recently released the second edition of the Global Healthspan Report, which presents new evidence that aging, once seen as an inevitable decline, can be managed through science, policy, and innovation to drive sustainable growth and wellbeing. Drawing on two global surveys and extensive investment data, the report positions healthspan, the years of life spent in good health, as both a catalyst for scientific and economic progress. Download here.

####

About Hevolution Foundation - Founded on the belief that every person has the right to live healthier, longer, Hevolution Foundation is a global catalyst, collaborator, and convener on a mission to drive efforts to extend healthspan and understand the biological processes behind aging. As a global nonprofit organization headquartered in Riyadh with a North American hub and an annual budget of up to $1 billion, Hevolution is supporting a cutting-edge, global ecosystem of talent to propel aging and geroscience research forward and achieve medical breakthroughs. With a focus on aging as a treatable process, Hevolution aims to increase the number of aging-related treatments on the market, compress the timeline of drug development, and increase accessibility to therapeutics that extend healthy lifespan, also known as healthspan. To date, Hevolution has committed about $400 million to drive scientific discoveries to make aging healthier for humanity, representing around 200 researchers and partnerships worldwide and several early-stage biotech impact investments. Connectwith Hevolution Foundation on LinkedIn, X (formerly Twitter), and at hevolution.com.

About AFAR - The American Federation for Aging Research (AFAR) is a national non-profit organization that supports and advances pioneering biomedical research that is revolutionizing how we live healthier and longer. For more than four decades, AFAR has served as the field’s talent incubator, providing $225,316,000 to 4,539 investigators at premier research institutions to date—and growing. In 2025, AFAR expects to provide approximately $12,816,000 to 79 investigators through a range of programs. A trusted leader and strategist, AFAR also works with public and private funders to steer high quality grant programs and inter-disciplinary research networks. AFAR-funded researchers are finding that modifying basic cellular processes can delay—or even prevent—many chronic diseases, often at the same time. They are discovering that it is never too late—or too early—to improve health. This groundbreaking science is paving the way for innovative new therapies that promise to improve and extend our quality of life—at any age. Learn more at www.afar.org.

END



ELSE PRESS RELEASES FROM THIS DATE:

GeoFlame VISION: Using AI and satellite imagery to predict future wildfire risk

2025-12-09
FOR IMMEDIATE RELEASE  EMBARGOED UNTIL DECEMBER 9, 2025  GeoFlame VISION: Using AI and Satellite Imagery to Predict Future Wildfire Risk  A new computer model produces a dynamic wildfire risk map,  starting with the state of California  Washington, D.C., December 9, 2025 – Wildfires pose a significant threat across the southwestern United States, due to the region’s unique topography and weather conditions. Accurately identifying locations at the highest risk of a severe wildfire is critical ...

Nationwide study suggests that water treatment methods may impact the risk of legionnaires’ disease

2025-12-09
FOR IMMEDIATE RELEASE  EMBARGOED UNTIL DECEMBER 9, 2025  Nationwide Study Suggests that Water Treatment Methods May Impact the Risk of Legionnaires’ Disease  Higher rates of disease are seen in zip codes served by water treatment plants that use chlorine as the primary disinfectant  Washington, D.C., December 9, 2025 – Preliminary results of a nationwide study suggest that the disinfectant used to treat water before it is distributed through pipes may impact the incidence of Legionnaire’s disease in certain parts of the country. The findings will be presented Dec. 9 at the annual meeting of the Society for Risk Analysis in Washington, D.C.   Waterborne ...

Oyster larvae on drugs move slowly and are stressed

2025-12-09
FOR IMMEDIATE RELEASE  EMBARGOED UNTIL DECEMBER 9, 2025  Oyster Larvae on Drugs Move Slowly and Are Stressed  Study finds that exposure to addictive drugs like fentanyl and ketamine affect the behavior and survival rates of oyster larvae   Washington, D.C., December 9, 2025 – The discharge and prevalence of psychoactive drugs in surface waters has raised concerns about potential risks to ecosystems and public health. Yet there is limited information on the ecotoxicity of these compounds in marine environments and aquaculture.  A study presented on Dec. 9 at the annual meeting of the Society for Risk Analysis in ...

Targeting a specific brain circuit may help prevent opioid relapse, WSU study finds

2025-12-09
PULLMAN, Wash. -- Washington State University researchers have discovered how a neural circuit – or a connection between two brain regions – drives relapse after opioid use, a finding that could lead to more effective treatments for opioid use disorders. In a study published in the Journal of Neuroscience, researchers in the Department of Integrative Physiology and Neuroscience at WSU’s College of Veterinary Medicine used a preclinical model to model opioid use in humans and found that reducing the activity within a specific neuronal ...

Tec-Dara combination offers substantial improvement over standard second-line therapies for relapsed or refractory multiple myeloma

2025-12-09
(ORLANDO, Dec. 9, 2025) Patients with relapsed or refractory (R/R) multiple myeloma who received a combination of teclistamab, a bispecific monoclonal antibody, and daratumumab, a CD38-directed monoclonal antibody, were 83% more likely to be alive without disease progression compared with those who received standard second-line therapies at a median of nearly 35 months of follow-up, according to the results of a new trial presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. The ...

Improving treatment for an autoimmune bleeding condition

2025-12-09
PHILADELPHIA – More than half of patients in a Phase III clinical trial who received a limited course of the experimental monoclonal antibody ianalumab for primary immune thrombocytopenia (ITP), an autoimmune disorder that can cause life-threatening bleeding, were able to maintain safe platelet counts without serious bleeding episodes for at least one year. The results were published today in the New England Journal of Medicine, by researchers from the Perelman School of Medicine at the University of Pennsylvania, and presented by collaborators at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition Orlando, Florida (LBA-2). ITP is an autoimmune condition where ...

Drug reduced need for blood transfusions during hospitalization for non-cardiac surgery

2025-12-09
(ORLANDO, Dec. 9, 2025) –– When hospitals were randomly assigned to treat patients undergoing higher-risk non-cardiac surgery with tranexamic acid (TXA) or a placebo, patients who received TXA needed significantly fewer blood transfusions and saw no increase in potentially life-threatening blood clots (thrombosis) after 90 days of follow-up, according to research presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. “Our findings confirm that TXA reduces the need for blood transfusion in patients ...

Novel agent ianalumab added to standard therapy extends time to treatment failure in patients with previously treated immune thrombocytopenia

2025-12-09
(ORLANDO, Dec. 9, 2025) Patients with immune thrombocytopenia (ITP) who received a first-in-class investigational drug in addition to standard therapy went longer without a bleeding episode that needed urgent treatment or needing another treatment for their ITP, compared with patients who received a placebo in addition to standard therapy. The study is the first to test a novel drug for ITP early in the disease course and was presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. “In patients for whom first-line therapy had stopped working, treatment ...

Pirtobrutinib outperforms bendamustine plus rituximab for previously untreated CLL/SLL

2025-12-09
(ORLANDO, Dec. 9, 2025) – In a new trial, the Bruton tyrosine kinase (BTK) inhibitor pirtobrutinib increased the rate of survival without disease progression and was well tolerated with a more favorable safety profile when compared with bendamustine plus rituximab (BR) in patients with previously untreated chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). The data were presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. “We were able to prove that pirtobrutinib is an excellent drug both in terms of efficacy and tolerance,” ...

Online tracking and privacy on hospital websites

2025-12-09
Researchers find that tracking pixels—small pieces of embedded code that can transmit user data to third parties—significantly increase data breach risk on hospital websites. Hilal Atasoy and colleagues analyzed 12 years of archived website data from 1,201 large US hospitals between 2012 and 2023, examining the adoption of pixel tracking and their relationship to data breaches. The authors found pixel tracking in 66% of hospital-year observations, despite stringent privacy regulations. Hospitals using third-party pixels experienced at least a 1.4 percentage point increase in breach probability, representing a 46% ...

LAST 30 PRESS RELEASES:

Antimicrobial effects of Syzygium aromaticum and Salvadora persica against common peri-implantitis pathogens in vitro

EVs pose no greater risk to pedestrians than conventional vehicles

Modeling microplastic accumulation under the ocean surface

Pompeii offers insights into ancient Roman building technology

University of Utah engineers give a bionic hand a mind of its own

Transient and long-term risks of common physical activities in people with low back pain

Health care contact days in older adults with metastatic cancer

Brain resilience science reshapes psychiatry from treating illness to building strength

An assessment of the antidepressant potential of deramciclane in two animal tests

Pitt and UPMC study finds epigenetic signature of pediatric traumatic brain injury, paves way for precision recovery tools

Brain discovery opens door to earlier detection of metabolic syndrome in women

SwRI-led study provides insight into oscillations in solar flares

Announcing the third cohort of the Hevolution/AFAR new investigator awards in aging biology and geroscience research

GeoFlame VISION: Using AI and satellite imagery to predict future wildfire risk

Nationwide study suggests that water treatment methods may impact the risk of legionnaires’ disease

Oyster larvae on drugs move slowly and are stressed

Targeting a specific brain circuit may help prevent opioid relapse, WSU study finds

Tec-Dara combination offers substantial improvement over standard second-line therapies for relapsed or refractory multiple myeloma

Improving treatment for an autoimmune bleeding condition

Drug reduced need for blood transfusions during hospitalization for non-cardiac surgery

Novel agent ianalumab added to standard therapy extends time to treatment failure in patients with previously treated immune thrombocytopenia

Pirtobrutinib outperforms bendamustine plus rituximab for previously untreated CLL/SLL

Online tracking and privacy on hospital websites

A freely available tool to document wartime destruction

Residential solar panels can raise electricity rates

Scientists use synthetic platelets as ‘Trojan horse’ drug-delivery system

Cooperative Intermolecular Interactions Regulate Supramolecular Polymer Assembly

Korea University researchers develop ultrasensitive method to detect low-frequency cancer mutations

First patient enrolled in GOG-3133/ FRAmework-01 phase 3 study evaluating sofetabart mipitecan (LY4170156), a novel ADC targeting folate receptor alpha (FRα), in recurrent ovarian cancer

Two Hebrew University researchers win prestigious ERC consolidator grants

[Press-News.org] Announcing the third cohort of the Hevolution/AFAR new investigator awards in aging biology and geroscience research
$6,750,000 will support 18 junior investigators studying age-related diseases and healthspan